Please login to the form below

Not currently logged in
Email:
Password:

Lexicon Pharmaceuticals

This page shows the latest Lexicon Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits Zynquista alliance with Lexicon

Sanofi exits Zynquista alliance with Lexicon

Will pay $260m to end collaboration. Following rejection from the FDA earlier this year, Sanofi has agreed to pay Lexicon Pharmaceuticals $260m to end the alliance formed to develop and ... for demonstrating cardiovascular and renal benefits,” said

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type. Headline ($m). Selexys Pharmaceuticals/ Novartis. ... Strategic alliance, options. 122.7 per. BMS/ Lexicon Pharmaceuticals. BMS-986176 for neutopathic pain (pc) plus other small

  • Deal Watch November 2015 Deal Watch November 2015

    Staying with diabetes, so strategically important, Sanofi put in place a collaboration with Lexicon Pharmaceuticals for sotagliflozin (LX4211), an oral treatment for type 1 and type 2 diabetes. ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration,

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    For multivalent MVA-BN Filovirus vaccine. 187. Lexicon Pharmaceuticals/Ipsen. Licence [B]. Telotristat etiprate in P3 for carcinoid syndrome.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....